Patient Selection for Aflibercept 8 mg

Opinion
Video

Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
During the 2025 EURETINA congress, the Eye Care Network spoke with Mark Gillies, MD, PhD, director of research at the Save Sight Institute, about anti-VEGF agents.
© 2025 MJH Life Sciences

All rights reserved.